APOE and dementia: In conclusion, we demonstrate superior performance of the LC-MS platform over Simoa assays for plasma amyloid-β and p-tau181, and over a model incorporating age, sex and APOE ε4 carrier status, in screening for concurrent PET amyloid status in a large number of dementia-free individuals.